XW043RBIntroduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11
- Billable / Specific Code
- New for FY 2026
XW043RB is a billable ICD-10-PCS procedure code for Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | 4 | Central Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | R | Letetresgene Autoleucel |
| 7 | Qualifier | B | New Technology Group 11 |
Code History
- XW043FA — Introduce Non-CAR-T Ther in Central Vein, Perc, New Tech 10
Similar Procedure Codes
Questions About XW043RB
Is XW043RB a billable code?
Yes. XW043RB is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW043RB mean?
XW043RB breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character R is the Device/Substance/Technology (Letetresgene Autoleucel); the 7th character B is the Qualifier (New Technology Group 11).
